-
Clinical Ophthalmology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
Original Research
(3247) Views (684) Full article downloads
Authors: Ioannis D Ladas, Marilita M Moschos, Thanos D Papakostas, Athanasios I Kotsolis, Ilias Georgalas, Michail Apostolopoulos
Published Date December 2008
Volume 2009:3 Pages 129 - 131
DOI: http://dx.doi.org/10.2147/OPTH.S4625
Ioannis D Ladas, Marilita M Moschos, Thanos D Papakostas, Athanasios I Kotsolis, Ilias Georgalas, Michail Apostolopoulos
Department of Ophthalmology, “G. Gennimatas” Hospital of Athens, University of Athens, Athens, Greece
Purpose: The purpose of this observational case report is to describe a case of skin rash after intravitreal use of bevacizumab.
Methods: A 50-year-old man with choroidal neovascularization in the right eye due to age-related macular degeneration was treated with three intravitreal injections of bevacizumab.
Results: Twelve days after the first injection, the patient developed a maculopapular rash on his forehead and on both temporal regions around his eyes. The rash disappeared eight days after treatment with topical corticosteroids. A skin rash with the same distribution reappeared 14 days after the second and 10 days after the third injection. Similarly, it disappeared five and seven days after the use of the same treatment. The follow-up period was 15 months after the third injection. During the follow-up period the rash did not reappear.
Conclusion: This case report may initiate further investigation of similar cases to support this observation, as there are a lack of reports of skin rash after intravitreal administration of bevacizumab.
Keywords: skin rash, bevacizumab, age-related macular degeneration
Other articles by Dr Marilita Moschos
Acute visual loss and intraocular hemorrhages associated with endoscopic spinal surgery
Anterior segment granuloma and optic nerve involvement as the presenting signs of systemic sarcoidosis
Giant cell arteritis: A rare cause of posterior vasculitis
Quantitative determination of glycosaminoglycans in tears of diabetic patients
Readers of this article also read:
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
Wake up to insomnia: future approaches to the management of insomnia
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Journal Indexing
See where all the Dove Press journals are indexed
- Interested in being a peer-reviewer?
Click here to register.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia




